We’re thrilled to announce a major milestone in our mission to democratize access to robotics in rehabilitation. The ABLE Exoskeleton is now officially approved for use with a wide clinical variety.
Expanded Indications: Serving a Wider Range of Patients
🔹The ABLE Exoskeleton is now indicated for gait rehabilitation for people with mild to severe walking impairments caused by neurological conditions or muscular weakness. Initially, the device was indicated for specific conditions such as spinal cord injury (SCI), multiple sclerosis (MS), and neuromuscular disorders.
Now, it has been validated for use with a much wider range of patients, including those recovering from a stroke.
This expansion means the ABLE Exoskeleton can benefit a broader spectrum of patients, from those with mild gait issues to those with more severe impairments. As an adaptable tool, it delivers personalized rehabilitation for each user and their therapy goals, helping patients achieve better health outcomes and independence.
One device, Multiple Possibilities
For rehabilitation clinics, this update adds versatility. Therapists can apply their clinical expertise to treat diverse patients, using a single tool to address a wide range of needs. Our primary objective—and a key strategic milestone—is to expand this technology’s clinical reach, allowing more patients and therapists to benefit from its application in neurorehabilitation.
If you’re a clinic already working with ABLE Exoskeleton, you’re ready to expand its use.
Same device. More indications. Greater impact in neurorehabilitation.
📩 Want to Learn More?
👉 If you’re a clinic already working with ABLE Exoskeleton, you’re ready to expand its use.
👉 If not, we’d love to help you start. Contact us!
More patients. More possibilities. #ABLEMovesWithYou
